Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gestational diabetes and the human salivary microbiota: a longitudinal study during pregnancy and postpartum

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Not now but later - a qualitative study of non-exercising pregnant women's views and experiences of exercise

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fever in pregnancy and the risk of congenital malformations: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There are a lack of data regarding the effect of basal insulin analogues on rates of events like congenital malformation and perinatal mortality in diabetic pregnancy.

METHODS: The present study is a prospective, non-interventional, multicentre cohort study conducted in seven countries, designed to assess the safety of insulin detemir during pregnancy, and to monitor the health status of resulting infants (exposed in utero) up to 1 year of age. The study population includes women with type 1 or type 2 diabetes, who are pregnant and being treated with insulin. Data will be collected in the context of routine practice. The primary endpoint is the proportion of pregnancies in women treated with insulin detemir, compared with other basal insulin regimens, which do not result in any of the following events: major congenital malformations, perinatal death or neonatal death. A sample size of 3075 pregnancies was calculated to provide an 80% power to detect a difference of 3.5% between groups in the primary endpoint at a 5% level.

DISCUSSION: The study will also examine other important maternal endpoints (e.g., incidences of severe hypoglycaemia and pre-eclampsia) and perinatal outcomes such as overweight neonates, as well as infant outcomes at 1 year of age. It has a fixed recruitment period from 2013 to 2018, enrolling all eligible patients, and is expected to inform future prescribing with basal insulins in diabetic pregnancy.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT01892319 (date registered: 27.06.2013).

Original languageEnglish
JournalBMC Pregnancy and Childbirth
Volume17
Issue number1
Pages (from-to)e38
ISSN1471-2393
DOIs
Publication statusPublished - 18 Jan 2017

ID: 49765827